VERV Verve Therapeutics Inc.

FDA Catalyst Company
13.94
+0.15  (+1%)
Previous Close 13.79
Open 14.29
52 Week Low 11.295
52 Week High 78
Market Cap $678,340,557
Shares 48,661,446
Float 20,657,657
Enterprise Value $309,634,653
Volume 152,074
Av. Daily Volume 747,905
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
RBC Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/18/2022
Stifel Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/24/2021
William Blair Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/12/2021
Guggenheim Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/12/2021
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/12/2021
Jefferies Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/12/2021

Latest News

  1. Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023

    Preparing for Submission of United Kingdom and United States Regulatory Filings for VERVE-101 in Second Half of 2022

    Cash, Cash Equivalents and Marketable Securities of $323.3 Million with Cash Runway into 2024

    CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today outlined its global development strategy for its lead gene editing candidate, VERVE-101, and reported financial results for the first quarter ended March…

    View Full Article
  2. VERVE-101 Preclinical Data Package Supports Company's Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH

    Single Intravenous Infusion of VERVE-101 Clinical Formulation Led to Mean 68% Reduction in Plasma LDL-C in NHPs Out to One-Year with Good Tolerability; VERVE-101 Precursor Formulation Led to Durability of LDL-C Reduction Observed Out to More Than 20 Months

    In Vivo Delivery of Base Editors with Proprietary GalNAc-Lipid Nanoparticle Demonstrates Improved Potency Compared with Standard Lipid Nanoparticles, Including 98% Reduction in Blood ANGPTL3 in NHPs at Day 15

    CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care…

    View Full Article
  3. CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the following May investor conferences:

    • BofA Securities 2022 Healthcare Conference (formal presentation) on Wednesday, May 11, 2022, at 2:40 p.m. PT in Las Vegas; and,
    • 2022 RBC Capital Markets Global Healthcare Conference (fireside chat) on Wednesday, May 18, 2022, at 1:35 p.m. ET in NYC.

    Live webcasts will be available in the investor section of the company's website at www.vervetx.com and will be archived for 60 days following the presentations…

    View Full Article
  4. Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022

    Whole Genome Sequencing at 500X Coverage of Primary Human Liver Cells Treated with VERVE-101 Demonstrated No Increased Frequency of Adenine Editing Compared to Untreated Controls

    CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced new findings from a comprehensive off-target assessment of its lead product candidate, VERVE-101, demonstrating minimal to no off-target editing and supporting the favorable tolerability…

    View Full Article
  5. Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs

    Data to be Presented Today at the American College of Cardiology 71st Annual Scientific Session & Expo

    CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, reported updated preclinical data in non-human primates (NHPs) showing durable and well-tolerated editing of the ANGPTL3 gene following administration of the company's ANGPTL3 base editor, supporting its potential as a treatment for atherosclerotic cardiovascular disease (ASCVD). In addition, the company provided…

    View Full Article
View All Verve Therapeutics Inc. News